The 21% CR rate was based on a subgroup analysis of patients with AML with mutant TP53 who received a 10-day course of decitabine; it is unclear how many patients in this subgroup had complex karyotype AML (11). The gene discussed is TP53; the disease is acute myeloid leukemia.